Tandem Diabetes Care (TNDM)
(Delayed Data from NSDQ)
$45.57 USD
+1.27 (2.87%)
Updated Aug 27, 2024 03:59 PM ET
After-Market: $45.60 +0.03 (0.07%) 5:16 PM ET
3-Hold of 5 3
D Value C Growth B Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$45.57 USD
+1.27 (2.87%)
Updated Aug 27, 2024 03:59 PM ET
After-Market: $45.60 +0.03 (0.07%) 5:16 PM ET
3-Hold of 5 3
D Value C Growth B Momentum C VGM
Zacks News
Here's Why You Should Hold on to Tandem (TNDM) Stock for Now
by Zacks Equity Research
Investor confidence in Tandem Diabetes (TNDM) is still high on several positive factors.
Tandem's (TNDM) Q1 Loss Wider Than Expected, Sales Top Mark
by Zacks Equity Research
Tandem's (TNDM) introduction of t:slim X2 with Basal-IQ technology, ramped-up supply capacity along with its global launch, substantially drive its top line in Q1.
Will Tandem Diabetes (TNDM) Report Negative Earnings Next Week? What You Should Know
by Zacks Equity Research
Tandem Diabetes (TNDM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
What's in Store for Tandem Diabetes' (TNDM) Q1 Earnings?
by Zacks Equity Research
The roll-out of Tandem Diabetes' (TNDM) unique insulin pump platform viz. t:slim X2 with Basal-IQ technology is expected to drive the top line in first-quarter 2019.
Tandem Diabetes (TNDM) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Tandem Diabetes (TNDM) closed at $62.37 in the latest trading session, marking a +0.68% move from the prior day.
Should First Trust Small Cap Growth AlphaDEX Fund (FYC) Be on Your Investing Radar?
by Sweta Killa
Style Box ETF report for FYC
Tandem Diabetes (TNDM) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Tandem Diabetes (TNDM) closed at $63.76, marking a +1.21% move from the previous day.
Why Is Tandem Diabetes (TNDM) Up 1.8% Since Last Earnings Report?
by Zacks Equity Research
Tandem Diabetes (TNDM) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Tandem Diabetes (TNDM) Hits a 52-Week High on Solid Prospects
by Zacks Equity Research
Tandem Diabetes Care's (TNDM) growth in pump shipments drives the top line significantly.
Tandem Diabetes Signs as an Insulin Pump Vendor in Canada
by Zacks Equity Research
Tandem Diabetes' (TNDM) insulin pump seems to be a strategic fit and well-timed from its massive uptake by the diabetic patients in Canada.
Tandem's Global Growth a Boost, Operating Losses a Bane
by Zacks Equity Research
Tandem's (TNDM) t:slim X2 Insulin Pump clinching a commercial license in Canada during Q4 is a tailwind.
Here's Why You Should Invest in Chemed (CHE) Stock Right Now
by Zacks Equity Research
Chemed (CHE) sees revenue growth across its wholly-owned subsidiaries, VITAS Healthcare and Roto-Rooter. Its capital deployment policy is based on buyouts and solid return of cash to shareholders.
Tandem (TNDM) Posts Earnings in Q4, Revenues Top Estimates
by Zacks Equity Research
The roll-out of t:slim X2 with Basal-IQ technology, increased supply capacity and renewal sales, as well as the international launch, drive Tandem's (TNDM) Q4 revenues.
Tandem, MGM, Meritage, KB Home and Lennar highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
Tandem, MGM, Meritage, KB Home and Lennar highlighted as Zacks Bull and Bear of the Day
Bull of the Day: Tandem Diabetes Care (TNDM)
by Kevin Cook
FDA approval of its latest smart insulin pump has revived investor faith in shares that once traded above $300
What's in Store for Tandem Diabetes' (TNDM) Q4 Earnings?
by Zacks Equity Research
Strong domestic sales along with the launch of the t:slim X2 Insulin Pump in select international markets are likely to drive Tandem Diabetes' (TNDM) Q4 earnings.
4 Dark Horse Stocks Ready to Explode in 2019
by Tirthankar Chakraborty
We highlight a few dark horse stocks that could come up with better-than-expected results this year and won't burn a hole in your pocket
Is Tandem Diabetes Care (TNDM) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Is (TNDM) Outperforming Other Medical Stocks This Year?
Here's Why You Should Buy Tandem Diabetes (TNDM) Stock Now
by Zacks Equity Research
Strength in domestic sales along with the recent launch of the t:slim X2 Insulin Pump in selected international markets bode well for Tandem Diabetes (TNDM).
Best Sector of 2018 and its Hit ETFs & Stocks
by Sweta Killa
Healthcare was the best-performing sector of 2018 and we have highlighted top-performing ETFs and stocks from this sector.
Implied Volatility Surging for Tandem Diabetes (TNDM) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Tandem Diabetes (TNDM) stock based on the movements in the options market lately.
Why Is Tandem Diabetes (TNDM) Down 9.4% Since Last Earnings Report?
by Zacks Equity Research
Tandem Diabetes (TNDM) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
DexCom Amends Deal With Verily to Launch Advanced CGM by 2020
by Zacks Equity Research
DexCom (DXCM) and Verily to collaborate on the development of additional products and software based on DexCom's profile in the future.
Tandem Diabetes (TNDM) Reports Loss in Q3, Revenues Beat
by Zacks Equity Research
Impressive domestic sales along with the recent launch of the t:slim X2 Insulin Pump in select international markets drove Tandem Diabetes' (TNDM) revenue beat in Q3.
What's in Store for Tandem Diabetes' (TNDM) Q3 Earnings?
by Zacks Equity Research
Strong domestic sales along with the recent launch of the t:slim X2 Insulin Pump in selected international markets likely to drive Tandem Diabetes' (TNDM) Q3 earnings.